Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 15/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 5/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11807328 | 0.96 | ALDH1A1 (0.58) | ALDH1A1CYP2C19CYP2C9SMN1; SMN2PKM | |
| SCHEMBL11720631 | 0.95 | ALDH1A1 (0.60) | ALDH1A1CYP2C19CYP2C9SMN1; SMN2PKM | |
| SCHEMBL16321748 | 0.79 | ALDH1A1 (0.54) | ALDH1A1CYP2C19CYP2C9SMN1; SMN2PKM | |
| SCHEMBL1944522 | 0.75 | ALDH1A1 (0.58) | ALDH1A1CYP2C19CYP2C9SMN1; SMN2PKM | |
| SCHEMBL3472019 | 0.74 | ALDH1A1 (0.60) | ALDH1A1CYP2C19CYP2C9SMN1; SMN2PKM | |
| SCHEMBL1947746 | 0.74 | ALDH1A1 (0.60) | ALDH1A1CYP2C19CYP2C9SMN1; SMN2PKM | |
| SCHEMBL11816698 | 0.73 | ALDH1A1 (0.61) | ALDH1A1CYP2C19CYP2C9SMN1; SMN2PKM | |
| SCHEMBL11811075 | 0.73 | ALDH1A1 (0.56) | ALDH1A1CYP2C19CYP2C9SMN1; SMN2PKM | |
| SCHEMBL3470758 | 0.71 | ALDH1A1 (0.54) | ALDH1A1CYP2C19CYP2C9SMN1; SMN2PKM | |
| SCHEMBL11784257 | 0.71 | ALDH1A1 (0.97) | ALDH1A1CYP2C19CYP2C9SMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678181-B1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2008-12-31 | — | — | EP | disclosed |
| US-7449473-B2 | Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1678181-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050119287-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2005-06-02 | — | — | US | disclosed |
| WO-2005042534-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119287-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA3 | ALDH1A1 1178/4885CYP2C19 705/4885CYP2C9 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.